Sudeep Pharma enterprise value

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026
10,843—
53.826.7
15.514.8
148148
10,953—
94.5122
₹969.74—
1,1211,046
13.2%14.2%
0.01×—
15.43×—
43.69×—
46.89×—
Reference items — trailing FY values
710642
251222
234207
—69.6
−48.6−48.6
—−51.3
—118
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SUDEEPPHRM₹960.00

Sudeep Pharma Ltd.

· Chemicals
₹ CrorePeersSUDARSCHEMSTYRENIXSHARDACROPREFEXRCFRALLISRAINPRIVISCLMcap ₹10,843 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization—10,843.1
- Cash, Equiv & ST Investments26.753.8
+ Minority Interest14.815.5
+ Total Debt148.3148.3
Enterprise Value—10,953.1
Net Debt (memo)121.594.5
EV per Share—969.74
Total Capital1,046.41,121.1
Total Debt/Total Capital14.1713.23
Total Debt/EV—0.01
EV/Sales—15.43
EV/EBITDA—43.69
EV/EBIT—46.89
Reference Items — Trailing FY Values
Sales642.3709.6
EBITDA221.9250.7
EBIT207.1233.6
Operating Cash Flow69.6—
Free Cash Flow-48.6-48.6
FCFF (free cash flow to the firm)-51.3—
Capital Expenditure118.1—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.